Revance Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
RVNC Nasdaq 2834 https://www.revance.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Revance Therapeutics Inc

How Much Upside is Left in Revance Therapeutics (RVNC)? Wall Street Analysts Think 55.02% - Aug 29th, 2024 1:55 pm
Can Revance Therapeutics (RVNC) Climb 98.64% to Reach the Level Wall Street Analysts Expect? - Aug 13th, 2024 1:55 pm
Sector Update: Health Care Stocks Slipping Late Afternoon - Aug 12th, 2024 7:54 pm
Crown Laboratories, Revance Enter Merger Agreement - Aug 12th, 2024 1:27 pm
Botox rival Revance to go private in $924 million deal - Aug 12th, 2024 12:15 pm
Crown Laboratories and Revance Announce Entry Into Merger Agreement - Aug 12th, 2024 12:00 pm
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Misses Revenue Estimates - Aug 8th, 2024 10:00 pm
Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update - Aug 8th, 2024 8:05 pm
Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024 - Aug 1st, 2024 8:05 pm
Stocks to Buy: 3 Breakout Stars to Transform Your Portfolio - Jul 11th, 2024 10:00 am
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 14th, 2024 8:05 pm
Revance to Participate in Upcoming Investor Conferences - May 28th, 2024 8:05 pm
Revance Therapeutics (RVNC) Loses -18.85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - May 24th, 2024 1:35 pm
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains - May 23rd, 2024 12:50 am
3 Underappreciated Stocks That Could 10x in 10 Years - May 12th, 2024 8:00 pm
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2024 Earnings Call Transcript - May 10th, 2024 8:30 pm
Revance Therapeutics Reports Q1 2024 Financial Results: Revenue Growth Amidst Rising Operating ... - May 10th, 2024 7:04 pm
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Lags Revenue Estimates - May 9th, 2024 10:25 pm
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update - May 9th, 2024 8:06 pm
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia - May 9th, 2024 8:05 pm